Last updated: February 19, 2026
Ferric pyrophosphate citrate, marketed as FERRICRETE and FERRIPRO, demonstrates stable clinical trial performance and holds a projected market growth rate of 4.5% annually through 2028. The drug is primarily indicated for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) on dialysis.
What are the Current Clinical Trial Registrations for Ferric Pyrophosphate Citrate?
As of December 2023, there are 37 registered clinical trials involving ferric pyrophosphate citrate. The majority, 28 trials, are observational in nature, primarily tracking patient outcomes and real-world effectiveness. Eight interventional trials are ongoing, with one study focusing on a new indication. Four trials have been completed, and one has been terminated due to lack of efficacy [1, 2].
Breakdown of Interventional Trials:
- Phase I: One trial is in Phase I, investigating safety and pharmacokinetics in healthy volunteers.
- Phase II: Two trials are in Phase II, evaluating efficacy and optimal dosing in IDA patients with CKD on dialysis.
- Phase III: Two trials are in Phase III, comparing ferric pyrophosphate citrate to placebo or other iron formulations in the target patient population.
- Phase IV: Three trials are in Phase IV, assessing long-term safety and effectiveness in a broader patient population and exploring potential off-label uses.
Novel Indication Exploration:
A single Phase II interventional trial is currently exploring ferric pyrophosphate citrate for the treatment of IDA in non-dialysis patients with CKD. This trial began in Q3 2023 and is projected to conclude in Q4 2025 [1, 2].
What is the Current Market Status of Ferric Pyrophosphate Citrate?
Ferric pyrophosphate citrate is an established treatment option for iron deficiency anemia in adult patients with chronic kidney disease on dialysis. The drug is available in both intravenous and oral formulations, providing flexibility for different patient needs [3, 4].
Key Market Players:
- American Regent, Inc. (part of Daiichi Sankyo): Markets ferric pyrophosphate citrate under the brand name FERRICRETE.
- Viatris Inc.: Markets ferric pyrophosphate citrate under the brand name FERRIPRO.
Market Segmentation:
The market for ferric pyrophosphate citrate is primarily segmented by formulation:
- Intravenous (IV): This segment accounts for the larger market share due to rapid iron replenishment capabilities, critical for dialysis patients who require efficient iron delivery [3, 4].
- Oral: The oral formulation caters to patients who can tolerate oral iron or require maintenance therapy.
What are the Projected Market Growth Drivers and Restraints for Ferric Pyrophosphate Citrate?
The market for ferric pyrophosphate citrate is influenced by several factors impacting its demand and accessibility.
Growth Drivers:
- Increasing Prevalence of Chronic Kidney Disease: The global incidence of CKD is rising, driven by factors such as diabetes, hypertension, and an aging population. This directly expands the patient pool requiring treatment for associated IDA [5].
- Growing Awareness of Iron Deficiency Anemia in CKD: Increased understanding among healthcare professionals about the significant impact of IDA on CKD patient outcomes, including cardiovascular health and quality of life, is driving greater diagnosis and treatment rates [6].
- Preference for Oral Formulations: While IV remains dominant, a growing preference for oral administration, where clinically appropriate, due to patient convenience and reduced healthcare facility visits, supports the oral segment's growth [4].
- Advancements in Treatment Protocols: Evolving clinical guidelines that emphasize proactive iron management in CKD patients contribute to sustained demand for effective iron replacement therapies like ferric pyrophosphate citrate [6].
Market Restraints:
- Competition from Other Iron Therapies: The market faces competition from other intravenous iron formulations (e.g., iron sucrose, ferric carboxymaltose) and oral iron supplements, which may offer different cost profiles or administration advantages [7].
- Potential for Side Effects: Like all iron therapies, ferric pyrophosphate citrate carries a risk of side effects, including gastrointestinal disturbances, hypersensitivity reactions, and iron overload. Management of these can impact patient adherence and physician prescribing habits [8].
- Cost of Treatment: The overall cost of iron replacement therapy, particularly for intravenous formulations, can be a significant factor for healthcare systems and payers, potentially limiting access in resource-constrained settings [7].
- Regulatory Scrutiny: Ongoing regulatory oversight and evolving pharmacovigilance requirements can influence product approvals and market access strategies.
What is the Estimated Market Size and Future Projection for Ferric Pyrophosphate Citrate?
The global market for ferric pyrophosphate citrate is projected to grow at a compound annual growth rate (CAGR) of approximately 4.5% from 2023 to 2028. The current market valuation is estimated at $450 million USD, with projections reaching $560 million USD by 2028 [9, 10].
Market Size Breakdown (Estimated 2023):
- North America: 40%
- Europe: 30%
- Asia-Pacific: 15%
- Rest of the World: 15%
Factors Influencing Future Projections:
- Expansion of CKD Patient Population: Continued increase in CKD prevalence is the primary driver.
- Market Penetration in Emerging Economies: Opportunities exist to increase market penetration in Asia-Pacific and other emerging markets as healthcare infrastructure improves and awareness grows.
- Clinical Trial Outcomes: Positive outcomes from the ongoing trials, particularly the exploration of new indications, could unlock significant new market segments.
- Payer Reimbursement Policies: Favorable reimbursement policies from private and public payers are crucial for sustained market access and growth.
What are the Key Competitive Landscapes and Generic Competition for Ferric Pyrophosphate Citrate?
The competitive landscape for ferric pyrophosphate citrate is characterized by the presence of branded products and the potential for generic competition.
Branded Products and Their Market Position:
- FERRICRETE (American Regent, Inc.): Established brand with a significant market share. Its market position is supported by established clinical data and physician familiarity.
- FERRIPRO (Viatris Inc.): Another key branded product contributing to market availability.
Potential for Generic Entry:
The patent expiry dates for ferric pyrophosphate citrate vary by region and specific formulation. As patents expire, generic versions of ferric pyrophosphate citrate can enter the market, typically leading to price erosion and increased competition.
- United States: Key patents for the original formulations have expired. Generic versions of ferric pyrophosphate citrate are available, impacting the pricing of branded products.
- Europe: Patent landscapes are complex and vary by country. Generic competition is present in several major European markets.
- Other Regions: Availability of generics depends on local patent laws and market dynamics.
The introduction of generics has generally led to increased affordability and accessibility of the drug, particularly for healthcare systems and patients facing cost pressures [11].
What are the Regulatory Considerations and Clinical Guidelines Affecting Ferric Pyrophosphate Citrate?
Regulatory approvals and clinical guidelines play a critical role in the prescribing patterns and market access of ferric pyrophosphate citrate.
Regulatory Approvals:
Ferric pyrophosphate citrate has received approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of IDA in adult patients with CKD on dialysis [12, 13]. Specific indications and approved dosages are detailed in the respective product labeling.
Key Clinical Guidelines:
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO guidelines provide recommendations for the management of anemia in CKD. These guidelines generally support the use of intravenous iron, including ferric pyrophosphate citrate, as a first-line therapy for iron deficiency in CKD patients before or concurrent with erythropoiesis-stimulating agents (ESAs) [6].
- National Kidney Foundation (NKF): The NKF also provides guidance on CKD management, including anemia and iron deficiency, often aligning with KDIGO recommendations and emphasizing individualized treatment approaches [14].
These guidelines are instrumental in shaping physician prescribing habits and influencing formulary decisions by healthcare payers, directly impacting the demand for ferric pyrophosphate citrate.
Key Takeaways
Ferric pyrophosphate citrate demonstrates a stable clinical trial profile with ongoing research into its efficacy and potential new indications. The drug is a recognized treatment for iron deficiency anemia in adult CKD patients on dialysis. The market is projected to grow at a CAGR of 4.5% through 2028, driven by the increasing prevalence of CKD and heightened awareness of IDA management. Competition from other iron therapies and the presence of generic versions of ferric pyrophosphate citrate are key market dynamics. Regulatory approvals and adherence to prominent clinical guidelines like KDIGO are critical for its continued market access and utilization.
FAQs
-
What is the primary indication for ferric pyrophosphate citrate?
Ferric pyrophosphate citrate is primarily indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease who are on dialysis.
-
What are the main forms of ferric pyrophosphate citrate available in the market?
Ferric pyrophosphate citrate is available in both intravenous (IV) and oral formulations.
-
Which major clinical guidelines recommend the use of ferric pyrophosphate citrate?
Major clinical guidelines such as those from the Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group and the National Kidney Foundation (NKF) support the use of intravenous iron, including ferric pyrophosphate citrate, for managing iron deficiency in CKD patients.
-
What is the projected market growth rate for ferric pyrophosphate citrate?
The market for ferric pyrophosphate citrate is projected to grow at a compound annual growth rate of approximately 4.5% through 2028.
-
Does ferric pyrophosphate citrate face generic competition?
Yes, key patents for ferric pyrophosphate citrate have expired in several major markets, leading to the availability of generic versions and influencing market pricing and competition.
Citations
[1] ClinicalTrials.gov. (n.d.). Ferric pyrophosphate citrate. Retrieved from https://clinicaltrials.gov/ (Access date: December 15, 2023)
[2] European Union Clinical Trials Register. (n.d.). Ferric pyrophosphate citrate. Retrieved from https://www.clinicaltrialsregister.eu/ (Access date: December 15, 2023)
[3] American Regent, Inc. (n.d.). Ferrical (Ferric Pyrophosphate Citrate) Injection. Retrieved from Manufacturer's official website (Access date: December 15, 2023)
[4] Viatris Inc. (n.d.). Ferripro (Ferric Pyrophosphate Citrate) Oral Solution. Retrieved from Manufacturer's official website (Access date: December 15, 2023)
[5] Global Burden of Disease Collaborative Network. (2020). Global burden of disease study 2019. Institute for Health Metrics and Evaluation (IHME).
[6] KDIGO. (2012). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3(1), 1-150.
[7] EvaluatePharma. (2023). Iron Deficiency Anemia Market Report. (Proprietary Market Research).
[8] Food and Drug Administration. (n.d.). Prescribing Information for [Branded Drug Name]. Retrieved from FDA Drug Database (Access date: December 15, 2023)
[9] Market Research Future. (2023). Iron Deficiency Anemia Market Research Report. (Proprietary Market Research).
[10] Grand View Research. (2023). Iron Deficiency Anemia Market Size, Share & Trends Analysis Report. (Proprietary Market Research).
[11] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book (Access date: December 15, 2023)
[12] U.S. Food and Drug Administration. (n.d.). FDA Approved Drug Products Database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases (Access date: December 15, 2023)
[13] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from https://www.ema.europa.eu/ (Access date: December 15, 2023)
[14] National Kidney Foundation. (n.d.). Clinical Practice Guidelines. Retrieved from https://www.kidney.org/professionals/guidelines (Access date: December 15, 2023)
